All News

While digital health companies strive to address important healthcare issues by developing products and service offerings in various categories such as genome sequencing, analytics, telemedicine, mobile apps, and population health management tools, little evidence is available in the digital space when it comes to peer-reviewed publications, measurement of potential impact, and effect on patients with the greatest burden of disease, says Meridith Peratikos, Director of Enterprise Research, axialHealthcare.

For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.

During the European Congress of Clinical Microbiology & Infectious Disease (ECCMID), being held in Amsterdam, the Netherlands, April 13-16, researchers are presenting findings that suggests the mode of delivery influences the development of gut microbiota in infants, regardless of a mother’s use of antibiotics, which could then affect infants’ respiratory health during his or her first year.

This week, the top managed care news included CDC clarifying its opioid guidelines for chronic pain; pharmacy benefit managers testifying before a Senate committee; Sanofi expanding its insulin savings program starting in June.

When antibiotics were discovered, they were considered a miracle. Decades of overuse have created a current public health crisis with a growing number of antibiotic-resistant bacteria. However, not all hope is lost in the fight against antibiotic resistance. There are programs in place to promote judicious use of antibiotics and policies and funding to help incentivize development of new antibiotics.

A recently published study looked to evaluate the effect of a single dose of nilotinib (Tasigna) in patients with PD. While nilotinib is FDA approved for the treatment of adult patients with chronic myeloid leukemia and not PD, the drug is able to penetrate the blood-brain barrier and reduce inflammation as well as lower levels of a toxic protein that prevents the brain from utilizing dopamine stored in vessels in areas of the brain that may control movement.

Researchers of a recently published study used preclinical behavioral models of migraine to determine that the application of calcitonin gene-related peptide (CGRP) to the dura mater, or the protective outer layer between the skull and the brain, in mice triggers pain responses only in females.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text